Compare RPID & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPID | WD |
|---|---|---|
| Founded | 2006 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.6M | 2.8B |
| IPO Year | 2021 | 2010 |
| Metric | RPID | WD |
|---|---|---|
| Price | $3.75 | $62.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.00 | ★ $96.00 |
| AVG Volume (30 Days) | 110.4K | ★ 273.0K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 4.28% |
| EPS Growth | N/A | ★ 20.18 |
| EPS | N/A | ★ 3.37 |
| Revenue | $30,523,000.00 | ★ $1,160,070,000.00 |
| Revenue This Year | $19.36 | $19.30 |
| Revenue Next Year | $21.48 | $10.04 |
| P/E Ratio | ★ N/A | $18.59 |
| Revenue Growth | 16.63 | ★ 17.65 |
| 52 Week Low | $0.87 | $60.72 |
| 52 Week High | $4.50 | $108.58 |
| Indicator | RPID | WD |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 36.14 |
| Support Level | $3.78 | $61.50 |
| Resistance Level | $4.07 | $64.62 |
| Average True Range (ATR) | 0.21 | 1.82 |
| MACD | -0.08 | 0.64 |
| Stochastic Oscillator | 20.93 | 41.95 |
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.